Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 27, 2026 10:00 ET | Source: Precedence Research

Atopic Dermatitis Market to Reach USD 12.97 Billion by 2034, Growing at 7.75% CAGR

The atopic dermatitis market size is predicted to grow from USD 6.14 billion in 2024 to USD 12.97 billion by 2034, driven by a CAGR of 7.75%.
January 27, 2026 09:45 ET | Source: AstuteAnalytica India Pvt. Ltd.

Regenerative Medicine Market Review 2020-2024 and Forecast 2025-2033: A $578.29 Bn Opportunity Says Astute Analytica

Chicago, Jan. 27, 2026 (GLOBE NEWSWIRE) -- According to recent data from Astute Analytica, the global regenerative medicine market was valued at US$ 73.01 billion in 2024 and is projected to reach a...
January 27, 2026 08:30 ET | Source: CytoDyn Inc.

CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer

VANCOUVER, Washington, Jan. 27, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized...
January 27, 2026 08:00 ET | Source: Cloudbreak Pharma, Inc.

Cloudbreak Pharma Announces Successful End-of-Phase-2 Meeting and Alignment with FDA on Phase 3 Path Forward for CBT-004

CBT-004, if approved, would be the first and only treatment for pinguecula, an ophthalmic condition impacting more than 50 million people in the U.S. alone In prior studies, CBT-004 demonstrated an...
January 27, 2026 07:30 ET | Source: TG Therapeutics, Inc.

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy), to be presented at...
January 27, 2026 07:00 ET | Source: Transpire Bio

Transpire Bio’s ANDA for Generic Trelegy® Ellipta® Accepted for Filing by the U.S. FDA

SUNRISE, Fla., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Transpire Bio, an integrated clinical-stage biopharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic diseases,...
January 26, 2026 21:55 ET | Source: Twin Hospitality Group Inc.

Twin Hospitality Group Files Voluntary Chapter 11 Petitions to Strengthen Capital Structure

DALLAS, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Twin Hospitality Group Inc. (Nasdaq: TWNP), the parent company of Twin Peaks Restaurant, today announced it has commenced voluntary chapter 11 proceedings...
January 26, 2026 13:00 ET | Source: Lactalis Canada

iÖGO nanö Introduces Completely New Yogurt Experience with Bubbles Innovation

TORONTO, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Canadian dairy leader Lactalis Canada today announced the launch of iÖGO nanö Bubbles – a first of its kind offering in the kids yogurt category featuring...
January 26, 2026 10:31 ET | Source: Diversified Royalty Corp.

Diversified Royalty Corp. Announces Amendment to AIR MILES® Licenses

VANCOUVER, British Columbia, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Diversified Royalty Corp. (TSX: DIV and DIV.DB.A) (the “Corporation” or “DIV”) is pleased to announce that its wholly-owned subsidiary...
January 26, 2026 07:10 ET | Source: Research and Markets

Autonomous Last Mile Delivery Market Report 2026: Outlook to 2031 with Shares and Development Insights Since 2021 - Featuring Starship Technologies, Drone Delivery Canada, Flytrex and More

Dublin, Jan. 26, 2026 (GLOBE NEWSWIRE) -- The "Autonomous Last Mile Delivery Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031" has been added to ...